Multivariable model for the occurrence of the primary endpoint
| HR 95% CI | χ2 | p Value | |
| Log transform of hsCRP, mg/l* | 1.31 (1.20 to 1.43) | 35.0 | <0.001 |
| Treatment group | 0.84 (0.70 to 0.99) | 3.9 | 0.048 |
| Multiple risk factors vs CVD | 0.56 (0.44 to 0.73) | 18.8 | <0.001 |
| Age, years | 1.05 (1.04 to 1.06) | 84.2 | <0.001 |
| Male | 1.45 (1.12 to 1.78) | 12.3 | 0.001 |
| BMI, kg/m2 | 0.98 (0.96 to 0.99) | 5.6 | 0.018 |
| Diabetes | 1.76 (1.45 to 2.14) | 32.7 | <0.001 |
| Hypertension | 1.05 (0.84 to 1.3) | 0.2 | 0.687 |
| Hypercholesterolaemia | 1.02 (0.81 to 1.28) | 0.0 | 0.885 |
| Current smoker | 1.29 (1.03 to 1.62) | 4.9 | 0.027 |
| Previous statins | 0.80 (0.65 to 0.99) | 4.0 | 0.045 |
| Previous angiotensin II antagonists | 1.00 (0.78 to 1.28) | 0.0 | 0.989 |
| Previous ramipril | 0.87 (0.64 to 1.2) | 0.8 | 0.363 |
| Aspirin daily dose, mg | 1.00 (1.00 to 1.006) | 3.8 | 0.052 |
↵* Per 1 SD increment.
BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; CVD, cardiovascular disease.